Welcome to our dedicated page for Ascentage Pharma Group International news (Ticker: AAPG), a resource for investors and traders seeking the latest updates and insights on Ascentage Pharma Group International stock.
Ascentage Pharma Group International reports recurring developments in cancer-focused drug commercialization and clinical development. The company is a global, commercial-stage integrated biopharmaceutical issuer with American depositary shares on Nasdaq and ordinary shares listed on HKEX. Its updates center on Olverembatinib, a third-generation BCR-ABL inhibitor approved in China, and Lisaftoclax, a China-developed Bcl-2 selective inhibitor, as well as oncology candidates such as Alrizomadlin, APG-2449, APG-5918 and APG-3288.
News from AAPG also covers clinical and preclinical data presented at oncology meetings, regulatory clearances for investigational studies, full-year financial results, commercial activity in China, pipeline progress in hematologic malignancies and solid tumors, and investor-conference communications.
Ascentage Pharma (NASDAQ: AAPG) will present four preclinical posters at the AACR Annual Meeting 2026 in San Diego, April 17–22, 2026. The abstracts cover olverembatinib (HQP1351), APG-2449, and APG-5918, reporting efficacy and synergies in multiple tumor models.
The posters detail combination activity with chemotherapy, BTK inhibition, MAPK blockade, and topoisomerase I inhibitors in endometrial, mantle cell, BRAF V600E-mutant, and small-cell lung cancer preclinical models. None of the three candidates are FDA approved.
Ascentage Pharma (NASDAQ: AAPG) will release its full year 2025 unaudited financial results and provide business updates on March 25, 2026 (7:00 pm EDT) / March 26, 2026 (HKT). The company will host investor webcasts in English and Chinese with live Q&A and a replay available for the English presentation.
Analysts and investors must register in advance to access the respective language webcasts; timings: Chinese webcast at 10:00 pm EDT on March 25, 2026, and English webcast at 8:00 am EDT on March 26, 2026.
Ascentage Pharma (NASDAQ: AAPG) said management will participate in three investor conferences: Oppenheimer (Feb 25 presentation), TD Cowen (Mar 4 fireside chat) and Jefferies Biotech on the Beach (Mar 10–11 meetings).
Webcasts for the presentation and fireside chat will be available via the Events page in the company's Investor Relations website.
Ascentage Pharma (NASDAQ: AAPG) announced management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026. The team will appear in a fireside chat at 9:30 am ET on Thursday, February 12, 2026.
The live webcast can be accessed via the Events page in the company's Investor Relations website.
Ascentage Pharma (NASDAQ: AAPG) announced that its next‑generation BTK degrader APG-3288 received IND clearance from the China Center for Drug Evaluation on Feb 5, 2026, following earlier U.S. FDA IND clearance.
The company will start a multicenter, open‑label Phase I study in relapsed/refractory hematologic malignancies to evaluate safety, tolerability, PK, and preliminary efficacy.
Ascentage Pharma (NASDAQ: AAPG) outlined its 2026 global innovation strategy at the 44th J.P. Morgan Healthcare Conference on Jan 15, 2026, highlighting a dual‑engine growth model led by commercial hematology drugs Olverembatinib and Lisaftoclax. The company received U.S. FDA IND clearance for APG-3288, a next‑generation BTK PROTAC degrader, and said multiple global registrational Phase III studies (GLORA, GLORA-4, POLARIS-1, POLARIS-2) are advancing. Other pipeline notes: APG-2449 entered global Phase III in NSCLC; APG-5918, APG-115, and APG-1252 progress in various indications. Commercial goals for 2026 include broader sales, coverage across 1,500 hospitals, and NRDL inclusion for Lisaftoclax in China.
Ascentage Pharma (NASDAQ:AAPG) announced that the U.S. FDA has granted IND clearance for APG-3288, a next-generation BTK-targeted protein degrader, enabling a global, multicenter, open-label Phase I study in patients with relapsed/refractory B-cell malignancies.
APG-3288 is a PROTAC-designed degrader intended to remove wild-type and multiple mutant BTK proteins, with preclinical data claiming higher potency, selectivity, and favorable PK versus other BTK degraders; clinical evaluation will assess safety, tolerability, PK, and preliminary efficacy.
Ascentage Pharma (NASDAQ: AAPG) said its management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Wednesday, January 14, 2026 at 2:15 p.m. PT. Ascentage Pharma is described as a global, commercial-stage, integrated biopharmaceutical company focused on discovery, development and commercialization of novel cancer therapies.
Ascentage Pharma (NASDAQ: AAPG) presented updated ASH 2025 data showing Olverembatinib (HQP1351) produced high response rates as second-line therapy in chronic-phase chronic myeloid leukemia (CP-CML).
Key metrics: CCyR 71.8% and MMR 43.6% in 39 efficacy-evaluable patients; among 30 patients who failed first-line second-generation TKIs, CCyR 76.7% and MMR 43.3%. Responses deepened over time, with MMR 60.0% at cycle 21. Safety profile was consistent with prior reports; no new safety signals and no on-study deaths.
Ascentage Pharma (NASDAQ:AAPG) presented first dataset from the global registrational Phase III POLARIS-1 study of olverembatinib plus low-intensity chemotherapy in newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) at ASH 2025.
Key results (as of July 18, 2025): among 53 efficacy-evaluable patients, 50 (94.3%) achieved CR/CRi; best MRD negativity 66.0% and MRD-negative CR 64.2% by end of three induction cycles. IKZF1plus subgroup showed 90% molecular response (9/10). Common grade ≥3 TEAEs included neutropenia 63.6%, thrombocytopenia 56.4%, and pneumonia 30.9%. POLARIS-1 was cleared by FDA and EMA; an option agreement with Takeda is in place for ex-China rights.